Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jade Ghosn

Showing results (191-200 of 267) with videos related to

Pageof 27
Sort By:
The Lancet. Infectious Diseases|May 29, 2021
Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre studyThomas Bettuzzi, Aurélie Jourdes, Olivier Robineau, et al.
International Journal of Sexual Health : Official Journal of the World Association for Sexual Health|August 22, 2025
Trajectories of Chemsex Engagement Across Time Among PrEP-Using Men Who Have Sex with Men: Results from the French ANRS-Prévenir CohortEmils Sietins, Luis Sagaon-Teyssier, Adbourahmane Sow, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 4, 2020
Case report study of the first five COVID-19 patients treated with remdesivir in FranceMarie Dubert, Benoit Visseaux, Valentina Isernia, et al.
Med (New York, N.Y.)|May 16, 2026
Expansion of NKG2A<sup>+</sup>CD8<sup>+</sup> T cells with regulatory signatures distinguish individuals living with HIV-2 from those with HIV-1Aurelio Orta Resendiz, Caroline Petitdemange, Marie Lazzerini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2024
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 InfectionAntoine Bachelard, Quentin Le Hingrat, Valentine-Marie Ferré, et al.
Open Forum Infectious Diseases|July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered QuestionsAnna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2021
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsCharlotte Charpentier, Alexandre Storto, Cathia Soulié, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2022
Histological Features Associated With Human Mpox Virus Infection in 2022 Outbreak in a Nonendemic CountryFaris Chalali, Marie Merlant, Audrey Truong, et al.
Microbiology Spectrum|September 20, 2022
Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological EfficacyValentine Marie Ferré, Nathan Peiffer-Smadja, Laura Kramer, et al.
Plos One|April 25, 2019
"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort studyPierre Gantner, Babacar Sylla, Laurence Morand-Joubert, et al.
Pageof 27

Showing results (191-200 of 267) with videos related to

Sort By:
Pageof 27
The Lancet. Infectious Diseases|May 29, 2021
Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre studyThomas Bettuzzi, Aurélie Jourdes, Olivier Robineau, et al.
International Journal of Sexual Health : Official Journal of the World Association for Sexual Health|August 22, 2025
Trajectories of Chemsex Engagement Across Time Among PrEP-Using Men Who Have Sex with Men: Results from the French ANRS-Prévenir CohortEmils Sietins, Luis Sagaon-Teyssier, Adbourahmane Sow, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 4, 2020
Case report study of the first five COVID-19 patients treated with remdesivir in FranceMarie Dubert, Benoit Visseaux, Valentina Isernia, et al.
Med (New York, N.Y.)|May 16, 2026
Expansion of NKG2A<sup>+</sup>CD8<sup>+</sup> T cells with regulatory signatures distinguish individuals living with HIV-2 from those with HIV-1Aurelio Orta Resendiz, Caroline Petitdemange, Marie Lazzerini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2024
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 InfectionAntoine Bachelard, Quentin Le Hingrat, Valentine-Marie Ferré, et al.
Open Forum Infectious Diseases|July 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered QuestionsAnna Maria Geretti, Marta Boffito, Stefano Bonora, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2021
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsCharlotte Charpentier, Alexandre Storto, Cathia Soulié, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 2022
Histological Features Associated With Human Mpox Virus Infection in 2022 Outbreak in a Nonendemic CountryFaris Chalali, Marie Merlant, Audrey Truong, et al.
Microbiology Spectrum|September 20, 2022
Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological EfficacyValentine Marie Ferré, Nathan Peiffer-Smadja, Laura Kramer, et al.
Plos One|April 25, 2019
"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort studyPierre Gantner, Babacar Sylla, Laurence Morand-Joubert, et al.
Pageof 27